Kyverna Therapeutics (KYTX) Cash & Equivalents (2023 - 2026)

Kyverna Therapeutics' Cash & Equivalents history runs 4 years deep, the most recent figure standing at $28.7 million for Q1 2026.

• Quarterly Cash & Equivalents fell 49.53% year-over-year to $28.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.7 million (down 49.53% YoY) and the FY2025 annual result came in at $124.1 million, up 28.43% from the prior year.
• Cash & Equivalents was $28.7 million for Q1 2026 at Kyverna Therapeutics, down from $124.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $224.3 million in Q1 2024 and bottomed at $23.0 million in Q3 2023.
• A 4-year average of $77.2 million and a median of $53.4 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents surged 463.73% — and 2025, when it sank 74.65%.
• Kyverna Therapeutics' Cash & Equivalents stood at $34.6 million in 2023, then jumped by 178.87% to $96.6 million in 2024, then gained by 28.43% to $124.1 million in 2025, then sank by 76.87% to $28.7 million in 2026.
• Business Quant data shows KYTX's Cash & Equivalents at $28.7 million in Q1 2026, $124.1 million in Q4 2025, and $34.2 million in Q3 2025.